Color Doppler Analysıs Of Uterin And Intraovarian Blood Flow Before And After Treatment Wıth Cabergoline In Hyperprolactinemic Patients

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01957839

Enrollment

Registered

2013-10-08

Start date

2010-03-31

Completion date

2011-09-30

Last updated

2013-10-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adverse Reaction to Other Drugs and Medicines

Brief summary

the investigators examined the hypothesis that hyperprolactinemia may alter uterin, endometrial and intraovarian blood flow and may contribute to increased infertility by another way.

Interventions

DRUGcabergoline treatment

cabergoline treatment for hyperprolactinemia group

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 40 Years

Healthy volunteers

Yes

Inclusion criteria

* Women who had blood prolactin level higher than 25ng/dl

Exclusion criteria

* Pregnancy * Use of drugs effecting vasculature such as hormonal therapy, oral contraceptives, antihypertensives * Diseases like pelvic inflammatory disease and systemic hypertension * Women with clinically overt or treated cardiovascular disease * Concurrent illness other than hyperprolactinemia

Design outcomes

Primary

Measure	Time frame
th effect of prolactin vascular flow and resistance	the effect of prolactin in vascular resistance at 2 weeks after treatment

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026